Genomma Lab InternacionalB de CV (MEX:LABB) Future 3-5Y EPS without NRI Growth Rate: N/A (As of Aug. 11, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:LABB Genomma Lab Internacional SAB de CV MEX:LABB
58 GF Score
Price MXN14.22
GF Value MXN17.12
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Genomma Lab InternacionalB de CV Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Genomma Lab InternacionalB de CV's Future 3-5Y EPS without NRI Growth Rate is N/A.

Genomma Lab InternacionalB de CV  (MEX:LABB) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Genomma Lab InternacionalB de CV Future 3-5Y EPS without NRI Growth Rate Related Terms

MEX:LABB vs ZTS, UTHR, VTRS: Future 3-5Y EPS without NRI Growth Rate Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genomma Lab InternacionalB de CV Future 3-5Y EPS without NRI Growth Rate vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Genomma Lab InternacionalB de CV's Future 3-5Y EPS without NRI Growth Rate falls into.


MEX:LABB
58GF Score
Genomma Lab Internacional SAB de CV MEX:LABB
Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?

Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued. The current stock price of MXN14.22 is trading 16.9% below its estimated GF Value™ of MXN17.12. GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.

Key valuation signals for MEX:LABB:

  • Future 3-5Y EPS without NRI Growth Rate: N/A
  • GF Value™: MXN17.12 vs. price of MXN14.22 (16.9% below fair value)
  • GF Score™: 58/100 with 3 warning signs

No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genomma Lab InternacionalB de CV Business Description

Other Exchanges GNMLF:USAGEKA:Germany
Address Avenida Antonio Dovali Jaime, Number 70, Tower C, Floor 2, Office A. Colonia Santa Fe, Del. Alvaro Obregon, Mexico, MEX, MEX, CP 01210
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
58GF Score

Get the complete analysis for MEX:LABB

Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN14.22
Price
MXN17.12
GF Value